Topic: Led by the ERS Assembly 11: Thoracic oncology, this journal club will explore the following paper: Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN); Lancet Oncol 2021; 22:51-56.
Who can participate? This is an open online event. However, the topic will be of particular interest to the members of ERS Assembly 11: Thoracic oncology, as well as non-members who specialise in this area. (Note: For the first journal club there will be no required pre-reading needed to participate)
Access: This is a virtual event. No registration is required. To participate, simply click on the link at the top of the page at the date and time of the event.
More from this journal club? This journal club will take place on a monthly basis. An email with details of each journal club session will be sent to you in advance.